KNECHT, H., Tomáš REIGL, M. KOTROVA, F. APPELT, P. STEWART, Vojtěch BYSTRÝ, Adam KREJČÍ, A. GRIONI, Karol PÁL, Kamila STRÁNSKÁ, Karla PLEVOVÁ, J. RIJNTJES, S. SONGIA, M. SVATON, E. FRONKOVA, J. BARTRAM, B. SCHEIJEN, D. HERRMANN, R. GARCIA-SANZ, J. HANCOCK, J. MOPPETT, J.J.M. VAN DONGEN, G. CAZZANIGA, F. DAVI, P.J.T.A. GROENEN, M. HUMMEL, E.A. MACINTYRE, K. STAMATOPOULOS, J. TRKA, A.W. LANGERAK, D. GONZALEZ, C. POTT, M. BRUGGEMANN and Nikos DARZENTAS. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia. London: Nature Publishing Group, 2019, vol. 33, No 9, p. 2254-2265. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-019-0499-4.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS
Authors KNECHT, H. (276 Germany), Tomáš REIGL (203 Czech Republic, belonging to the institution), M. KOTROVA (276 Germany), F. APPELT (276 Germany), P. STEWART (372 Ireland), Vojtěch BYSTRÝ (203 Czech Republic, belonging to the institution), Adam KREJČÍ (203 Czech Republic, belonging to the institution), A. GRIONI (380 Italy), Karol PÁL (703 Slovakia, belonging to the institution), Kamila STRÁNSKÁ (203 Czech Republic, belonging to the institution), Karla PLEVOVÁ (203 Czech Republic, belonging to the institution), J. RIJNTJES (528 Netherlands), S. SONGIA (380 Italy), M. SVATON (203 Czech Republic), E. FRONKOVA (826 United Kingdom of Great Britain and Northern Ireland), J. BARTRAM (528 Netherlands), B. SCHEIJEN (276 Germany), D. HERRMANN (276 Germany), R. GARCIA-SANZ (724 Spain), J. HANCOCK (826 United Kingdom of Great Britain and Northern Ireland), J. MOPPETT (826 United Kingdom of Great Britain and Northern Ireland), J.J.M. VAN DONGEN (528 Netherlands), G. CAZZANIGA (380 Italy), F. DAVI (250 France), P.J.T.A. GROENEN (528 Netherlands), M. HUMMEL (276 Germany), E.A. MACINTYRE (250 France), K. STAMATOPOULOS (300 Greece), J. TRKA (203 Czech Republic), A.W. LANGERAK (528 Netherlands), D. GONZALEZ (372 Ireland), C. POTT (276 Germany), M. BRUGGEMANN (276 Germany) and Nikos DARZENTAS (300 Greece, guarantor, belonging to the institution).
Edition Leukemia, London, Nature Publishing Group, 2019, 0887-6924.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 8.665
RIV identification code RIV/00216224:14740/19:00108523
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1038/s41375-019-0499-4
UT WoS 000484399300010
Keywords in English MINIMAL RESIDUAL DISEASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; CELL LYMPHOMA; IMMUNOGLOBULIN; PCR; STANDARDIZATION; PRIMERS; RELAPSE; RISK
Tags 14110212, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 8/3/2020 19:44.
Abstract
Assessment of clonality, marker identification and measurement of minimal residual disease (MRD) of immunoglobulin (IG) and T cell receptor (TR) gene rearrangements in lymphoid neoplasms using next-generation sequencing (NGS) is currently under intensive development for use in clinical diagnostics. So far, however, there is a lack of suitable quality control (QC) options with regard to standardisation and quality metrics to ensure robust clinical application of such approaches. The EuroClonality-NGS Working Group has therefore established two types of QCs to accompany the NGS-based IG/TR assays. First, a central polytarget QC (cPT-QC) is used to monitor the primer performance of each of the EuroClonality multiplex NGS assays; second, a standardised human cell line-based DNA control is spiked into each patient DNA sample to work as a central in-tube QC and calibrator for MRD quantification (cIT-QC). Having integrated those two reference standards in the ARResT/Interrogate bioinformatic platform, EuroClonality-NGS provides a complete protocol for standardised IG/TR gene rearrangement analysis by NGS with high reproducibility, accuracy and precision for valid marker identification and quantification in diagnostics of lymphoid malignancies.
Links
LM2015085, research and development projectName: CERIT Scientific Cloud (Acronym: CERIT-SC)
Investor: Ministry of Education, Youth and Sports of the CR, CERIT Scientific Cloud
NV16-34272A, research and development projectName: Encyklopedie CLL podskupin: unikátní znalostní databáze vybavená bioinformatickými nástroji použitelná v personalizované biomedicíně a klinické praxi
PrintDisplayed: 26/4/2024 07:07